U.S. Herbal Medicine Market Size, Share & Forecast 2026–2032

ID: MR-11448 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Herbal Medicine Market
  • ✓Market Size 2024: USD 11.8 billion
  • ✓Market Size 2032: USD 17.5 billion
  • ✓CAGR: 5.1%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Ginseng Export Permits Constrain Supply: Wild American ginseng exports require CITES Appendix II permits from the U.S. Fish and Wildlife Service, and unpermitted shipments face seizure. This concentrates raw supply among licensed dealers in Kentucky and Tennessee.
FINDING 02
Enforcement Consolidates Market Share: Contrary to the assumption that DSHEA deregulation sustains growth, FDA cGMP enforcement under 21 CFR Part 111 and FTC substantiation actions will eliminate small manufacturers after 2026. Share will consolidate toward Nature's Bounty Co. and Pharmavite.
ANALYST RECOMMENDATION

Analyst Recommendation — Qualify Suppliers Against USP Monographs: Buyers of bulk botanical raw materials should qualify suppliers against USP monographs and 21 CFR Part 111 identity testing before Q2 2026. Rising FDA warning letters and California Proposition 65 notices make undocumented lots a direct liability.

Herbal Medicine in the U.S.: Market Overview

The U.S. herbal medicine market reached USD 11.8 billion in 2024 and comprises botanical dietary supplements, herbal teas, tinctures, and standardised extracts sold through retail, pharmacy, and direct channels. Its structure is defined by the Dietary Supplement Health and Education Act of 1994, which classifies most botanicals as foods rather than drugs unless they are marketed with disease claims. That classification explains why the market scaled rapidly after 1994 and why it remains fragmented, with most participants competing on labelling, sourcing, and voluntary certification.

Government has dominated the legal definition of the market, while the private sector has led commercial development. Nature's Sunshine Products, Nature's Bounty Co., and Gaia Herbs compete on sourcing, extraction quality, and retail placement, and most launches require no federal premarket approval. Public institutions shape the evidence base rather than supply: the National Center for Complementary and Integrative Health at the National Institutes of Health funds botanical trials, while the U.S. Pharmacopeia's Dietary Supplement Verification Program offers voluntary quality certification that retailers increasingly demand.

Policy-Driven Growth in Herbal Medicine in the U.S.

Three policies drive demand. First, Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act, implemented through DSHEA, allows manufacturers to market structure-function claims, such as support for immune function or sleep quality, after notifying the FDA within 30 days of first marketing. This lowers launch costs and sustains a steady pipeline of new herbal formulations reaching shelves each year.

Second, the USDA Organic Cost Share Program reimburses 75 percent of annual organic certification costs, up to USD 750 per certified scope, under the National Organic Program at 7 CFR Part 205. This lowers entry barriers for domestic growers and supports organic-labelled herb premiums. Third, the Specialty Crop Block Grant Program, authorised under the Agricultural Marketing Act of 1946 and funded at USD 85 million annually by the Agriculture Improvement Act of 2018, finances state-level cultivation of medicinal crops such as echinacea and goldenseal, expanding domestic supply and stabilising ingredient pricing.

Regulatory Barriers and Compliance Costs

The most consequential barrier is 21 CFR Part 111, the FDA current good manufacturing practice rule for dietary supplements, which requires identity testing of each incoming botanical lot, contamination testing, and documented batch records. Administered by the FDA Human Foods Program, the rule falls disproportionately on small producers that lack in-house laboratories and must outsource testing. Separately, New Dietary Ingredient notifications under Section 413(d) of the FD&C Act must reach the FDA at least 75 days before marketing a novel botanical ingredient, delaying launches of new extracts.

California adds a second layer. Proposition 65, formally the Safe Drinking Water and Toxic Enforcement Act of 1986, requires a 60-day notice of intent to sue before enforcement, and the Office of Environmental Health Hazard Assessment sets maximum allowable dose levels for lead and other contaminants in botanicals. Imported herbs also face Prior Notice filings under Section 801(m) of the FD&C Act, added by the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, which must be lodged with the FDA before shipments reach U.S. ports.

Policy-Created Opportunities in U.S. Herbal Medicine

The FDA botanical drug pathway, set out in the agency's Botanical Drug Development guidance finalised in 2016, allows standardised botanical extracts to pursue Investigational New Drug and New Drug Application routes. Companies with clinically characterised extracts can move beyond supplement status into prescription-indication markets. Developers should pair early-phase trials with NCCIH-funded research collaborations to reduce clinical development costs.

The USDA Organic Cost Share Program creates a subsidised demand category for certified domestic herbs, and the Specialty Crop Block Grant Program funds grower capacity in states such as North Carolina and Kentucky. Cultivators who secure organic certification before the 2026 harvest qualify for both reimbursement and grant-funded cultivation trials. Processors can also apply for Specialty Crop Research Initiative grants administered by the USDA National Institute of Food and Agriculture for post-harvest standardisation.

Market at a Glance

MetricValue
Market Size 2024USD 11.8 billion
Market Size 2032USD 17.5 billion
Growth Rate (CAGR)5.1%
Most Critical Decision FactorFDA cGMP compliance under 21 CFR Part 111
Largest RegionSouth Region
Competitive StructureFragmented, with a long tail of independent manufacturers and multi-brand holding companies

Leading Market Participants

  • Nature's Sunshine Products
  • Nature's Bounty Co.
  • Pharmavite
  • Gaia Herbs
  • Traditional Medicinals
  • Herb Pharm
  • Nature's Way Products
  • Garden of Life
  • Twinlab Consolidated Holdings
  • Swanson Health Products

Regulatory and Policy Environment

The primary legislation is the Dietary Supplement Health and Education Act of 1994, which amended the Federal Food, Drug, and Cosmetic Act and is administered by the FDA Human Foods Program, which replaced the Center for Food Safety and Applied Nutrition in October 2024. Key requirements include 21 CFR Part 111 cGMP compliance, ingredient listing under the Dietary Supplement Listing Act of 2016, 30-day structure-function claim notifications, and serious adverse event reporting under the Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006. The Federal Trade Commission enforces advertising claims under Section 5 of the FTC Act.

Upcoming changes include the FSMA Section 204 food traceability rule, whose compliance date was extended to July 20, 2028, and which covers fresh herbs on the Food Traceability List. Compared with peers, the U.S. framework is permissive: Canada's Natural Health Products Regulations of 2004 require a product licence and Natural Product Number before sale, and the European Union's Directive 2004/24/EC requires registration of traditional herbal medicinal products against Committee on Herbal Medicinal Products standards that the U.S. does not impose.

Long-Term Policy Outlook for U.S. Herbal Medicine

By 2032, federal rulemaking will set enforceable heavy-metal limits for botanical ingredients, extending the Proposition 65 model nationally. The FDA will integrate adverse event reporting into electronic submission systems, raising compliance costs for manufacturers without digital quality management. Firms that cannot absorb these costs will exit, reducing the number of active supplement brands.

FTC enforcement of substantiation standards will intensify, shifting share toward firms holding clinical data. The FDA botanical drug pathway will convert several standardised extracts into prescription-indication products, creating a bifurcated market in which supplements compete on price and botanical drugs compete on evidence. Consolidation among Nature's Bounty Co., Nature's Sunshine Products, and Pharmavite will accelerate as independent manufacturers exit under compliance pressure.

Frequently Asked Questions

Most herbal products are regulated as dietary supplements under the Dietary Supplement Health and Education Act of 1994 unless they carry disease claims. Products marketed to treat or prevent disease fall under the FDA drug framework instead.
Manufacturers must submit a New Dietary Ingredient notification to the FDA under Section 413(d) of the FD&C Act at least 75 days before marketing. The notification must include safety information demonstrating that the ingredient is reasonably expected to be safe.
The rule requires identity testing of every incoming botanical lot and documented batch records, which small producers often outsource at additional cost. Non-compliance exposes firms to FDA warning letters and product holds.
Proposition 65 requires businesses to warn Californians about chemicals listed as causing cancer or reproductive harm, including lead found in some botanicals. Companies must serve a 60-day notice before enforcement actions proceed.
The Federal Trade Commission enforces advertising claims under Section 5 of the FTC Act, requiring competent and reliable scientific evidence for health claims. The FDA separately regulates labelling under the FD&C Act.

Market Segmentation

By Product Form
  • Capsules and Tablets
  • Tinctures and Liquid Extracts
  • Teas and Dried Herbs
  • Powders and Gummies
  • Standardised Botanical Extracts
By Distribution Channel
  • Mass Retail
  • Specialty Health Stores
  • E-commerce
  • Pharmacies
  • Direct Selling

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Herbal Medicine - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Form Insights
4.1 Capsules and Tablets
4.2 Tinctures and Liquid Extracts
4.3 Teas and Dried Herbs
4.4 Powders and Gummies
4.5 Others
Chapter 05 Distribution Channel Insights
5.1 Mass Retail
5.2 Specialty Health Stores
5.3 E-commerce
5.4 Pharmacies
5.5 Others
Chapter 06 Competitive Landscape
6.1 Market Players
6.2 Leading Market Participants
6.2.1 Nature's Sunshine Products
6.2.2 Nature's Bounty Co.
6.2.3 Pharmavite
6.2.4 Gaia Herbs
6.2.5 Traditional Medicinals
6.2.6 Herb Pharm
6.2.7 Nature's Way Products
6.2.8 Garden of Life
6.2.9 Twinlab Consolidated Holdings
6.2.10 Swanson Health Products
6.3 Regulatory Environment
6.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.